Inventiva SA has halted enrollment in its pivotal phase III Nativ3 trial with nonalcoholic steatohepatitis (NASH) candidate lanifibranor after a patient experienced raised liver enzymes indicative of autoimmune hepatitis. The resulting delays to the study could spell trouble for the firm, which estimates its cash runway will only see it through to the start of the third quarter 2024.
The Korean Research Institute of Bioscience and Biotechnology has synthesized peptides reported to be useful for the treatment of inflammatory disorders.
The Korean Research Institute of Bioscience and Biotechnology has synthesized peptides reported to be useful for the treatment of inflammatory disorders.
Recent genome-wide association studies have elucidated a spliced variant (rs72613567:TA) in 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) found to be associated with decreased risk of chronic liver disorders. The presence of this variant also correlates with delayed onset of autoimmune hepatitis in carriers.
Three papers accelerated through publication and appearing in Nature March 30, 2023, have linked an unexplained rise in cases of acute hepatitis in children to adeno-associated virus 2 (AAV2), and pointed to a possible immune-mediated trigger in patients who have a genetic predisposition.
Promidis Srl has presented results from preclinical evaluations of potent capsid assembly modulators (CAMs) to prevent abnormal accumulation of empty capsids and associated T-cell-mediated liver injury.
LONDON – Alentis Therapeutics SA is now equipped to deliver initial proof of concept for its universal approach to treating fibrosis, after raising $67 million in an oversubscribed series B.
MEXICO CITY – The 2019 International AIDS Society (IAS) Conference on HIV Science kicked off over the weekend with the usual pre-conference workshops, including a workshop by the IAS Towards an HIV Cure initiative.